Emcure Pharmaceuticals
NSE: EMCURE · ISIN INE168P01015 · Healthcare
₹2,228.00−52.00 (−2.28%)
Monday 9 November, 12:47 IST. Delayed. Source: Yahoo Finance.
Price chart
₹2,228.00 −52.00 (−2.28%) today
The day
- Previous close
- ₹2,280.00
- Open
- ₹2,270.00
- Day high
- ₹2,280.00
- Day low
- ₹2,196.60
Listed on NSE since 10 July 2024.
Key numbers
- Market value
- ₹41,979 Cr
- P/E (trailing)
- 38.40
- EPS (trailing)
- ₹57.63
- Price to book
- 7.86
- Dividend yield
- 0.16%
- Return on equity
- 21.4%
- Debt to equity
- 0.33
- Profit margin
- 10.7%
- Beta
- -0.00
- Volume today
- 1.96 L
- Average volume
- 1.86 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹5,931.08 Cr | ₹532.02 Cr |
| FY24 | ₹6,581.99 Cr | ₹498.18 Cr |
| FY25 | ₹7,808.27 Cr | ₹681.33 Cr |
| FY26 | ₹9,115.89 Cr | ₹924.36 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹2,820 Cr | ₹326 Cr | +33.7% |
| Q1 FY27Apr–Jun 2026 | ₹2,580 Cr | ₹294 Cr | +42.1% |
| Q4 FY26Jan–Mar 2026 | ₹2,470 Cr | ₹243 Cr | +28.8% |
| Q3 FY26Oct–Dec 2025 | ₹2,363 Cr | ₹231 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹2,270 Cr | ₹243 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹2,101 Cr | ₹207 Cr | – |
Source: Emcure Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Emcure Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹2,314 Cr | ₹2,132 Cr |
| Investments | ₹20 Cr | ₹20 Cr |
| Inventories | ₹2,505 Cr | ₹2,398 Cr |
| Owed by customers | ₹2,731 Cr | ₹2,563 Cr |
| Cash and equivalents | ₹137 Cr | ₹137 Cr |
| Total assets | ₹10,164 Cr | ₹9,612 Cr |
| Borrowings | ₹1,467 Cr | ₹1,204 Cr |
| Total liabilities | ₹4,820 Cr | ₹4,636 Cr |
| Shareholders’ equity | ₹5,344 Cr | ₹4,950 Cr |
Source: Emcure Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Pune
- Employees
- 6,914
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Emcure Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 3.60 Per Share
Dividend · ex-date 4 September 2026
- Dividend - Rs 3 Per Share
Dividend · ex-date 14 August 2025
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.